SARC Sarcoma SPORE View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2012-2018

FUNDING AMOUNT

11007192 USD

ABSTRACT

DESCRIPTION (provided by applicant): This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor; 3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma; and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9132690

Related SciGraph Publications

  • 2018-12. miR-133a function in the pathogenesis of dedifferentiated liposarcoma in CANCER CELL INTERNATIONAL
  • 2017-03-08. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation in NATURE COMMUNICATIONS
  • 2017-02. Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states in NATURE GENETICS
  • 2017. Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors in HDAC/HAT FUNCTION ASSESSMENT AND INHIBITOR DEVELOPMENT
  • 2016-11. Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53 in BRITISH JOURNAL OF CANCER
  • 2016-10. Liposarcoma: molecular targets and therapeutic implications in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2016-05. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy in BRITISH JOURNAL OF CANCER
  • 2016-04. Myogenic transcription factors regulate pro-metastatic miR-182 in ONCOGENE
  • 2016-02. Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein in ONCOGENE
  • 2016-01-21. Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish in NATURE COMMUNICATIONS
  • 2016-01. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics in MODERN PATHOLOGY
  • 2016. In Vivo Imaging of Cancer in Zebrafish in CANCER AND ZEBRAFISH
  • 2016. Allograft Cancer Cell Transplantation in Zebrafish in CANCER AND ZEBRAFISH
  • 2015-12. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway in MOLECULAR CANCER
  • 2015-09. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma in SCIENTIFIC REPORTS
  • 2015-08. The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma in LABORATORY INVESTIGATION
  • 2014-12. Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression in BMC CANCER
  • 2014-12. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy in BMC CANCER
  • 2014-06. Dystrophin is a tumor suppressor in human cancers with myogenic programs in NATURE GENETICS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "11007192"
        }, 
        "description": "DESCRIPTION (provided by applicant): This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor; 3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma; and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.", 
        "endDate": "2018-08-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2699159", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2699159"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "U54CA168512"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "excellent institution", 
          "non-profit organizations", 
          "SPORE mechanism", 
          "research", 
          "translational advances", 
          "profit consortium", 
          "University", 
          "Clinical Trials", 
          "prevention", 
          "NFI", 
          "multi-institution", 
          "diagnostics", 
          "outcome", 
          "clinical sarcoma research", 
          "malignant peripheral nerve sheath tumor", 
          "technological advances", 
          "development", 
          "therapeutic response", 
          "support", 
          "core", 
          "developmental pilot projects", 
          "SARC Sarcoma SPORE", 
          "advanced approach", 
          "identification", 
          "Harvard", 
          "major sarcoma", 
          "spore application", 
          "collaborative strengths", 
          "main goal", 
          "pediatric oncology", 
          "therapeutic target", 
          "application", 
          "Ewing's sarcoma", 
          "aggressive disease", 
          "unprecedented cooperation", 
          "developmental research programs", 
          "conduct", 
          "pathology", 
          "novel", 
          "tissue", 
          "investigation", 
          "Stanford University", 
          "Career Developmental Program", 
          "selection", 
          "therapeutic window", 
          "predictors", 
          "complex STS", 
          "institutions", 
          "commitment", 
          "biostatistics", 
          "treatment", 
          "National Center", 
          "talented young investigators", 
          "planning", 
          "excellence", 
          "description", 
          "applicants", 
          "mechanism", 
          "MRL", 
          "maximum advantage", 
          "improvement", 
          "biomarkers", 
          "new projects", 
          "HDACi", 
          "MD Anderson Cancer Center", 
          "researchers", 
          "spores", 
          "art research projects", 
          "receptors", 
          "multiple researchers", 
          "plan", 
          "quantitative imaging biomarkers", 
          "translational goals", 
          "SARC", 
          "sarcoma therapy", 
          "administration", 
          "project", 
          "protein", 
          "translation", 
          "bone sarcomas", 
          "soft tissue", 
          "program", 
          "therapeutic strategies", 
          "key individual researchers", 
          "major projects", 
          "NCI intramural program", 
          "Michigan", 
          "evaluation", 
          "advances", 
          "sarcoma", 
          "Columbia University", 
          "PET", 
          "state"
        ], 
        "name": "SARC Sarcoma SPORE", 
        "recipient": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/None", 
              "name": "SARC", 
              "type": "Organization"
            }, 
            "familyName": "BAKER", 
            "givenName": "LAURENCE HOWARD", 
            "id": "sg:person.057030230.15", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.057030230.15", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2699159"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2021-01-20T02:59", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_20.xml.gz", 
        "startDate": "2012-09-26T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9132690"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2699159'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2699159'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2699159'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2699159'


     

    This table displays all metadata directly associated to this object as RDF triples.

    136 TRIPLES      19 PREDICATES      113 URIs      106 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2699159 schema:about anzsrc-for:2211
    2 schema:amount N41e04eba63aa49f0a50c3fa03e8830d5
    3 schema:description DESCRIPTION (provided by applicant): This application represents unprecedented cooperation among excellent institutions, major sarcoma dedicated non-profit organizations, and the NCI intramural Program. This SPORE originates from SARC, a non-for-profit consortium that facilitates the conduct of research among national centers of excellence in sarcoma. The main goals of the SARC Sarcoma SPORE are the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and - particularly - advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, MD Anderson Cancer Center, and the NCI intramural program, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) HDACi-based therapeutic strategies for the treatment of genetically complex STS; 2) Identification of therapeutic windows for NFI-related malignant peripheral nerve sheath tumor; 3) Investigation of G-protein coupled receptors as biomarkers of aggressive disease and novel therapeutic targets in Ewing sarcoma; and 4) Development of quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy using advanced approaches in PET and MRl. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning; 2) Tissue and Pathology; 3) Clinical Trials; and 4) Biostatistics. The SPORE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also include a Career Developmental Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects, cores and programs are highly integrated and are poised to take maximum advantage of the SPORE mechanism to achieve translational goals. This SPORE joins state-of-the-art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce translational advances.
    4 schema:endDate 2018-08-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
    6 schema:identifier N29edb7c50c5c497fb942f8fb0effe64b
    7 Nbd41c90c083b440ea49f67b2baaf9b78
    8 schema:inLanguage en
    9 schema:keywords Career Developmental Program
    10 Clinical Trials
    11 Columbia University
    12 Ewing's sarcoma
    13 HDACi
    14 Harvard
    15 MD Anderson Cancer Center
    16 MRL
    17 Michigan
    18 NCI intramural program
    19 NFI
    20 National Center
    21 PET
    22 SARC
    23 SARC Sarcoma SPORE
    24 SPORE mechanism
    25 Stanford University
    26 University
    27 administration
    28 advanced approach
    29 advances
    30 aggressive disease
    31 applicants
    32 application
    33 art research projects
    34 biomarkers
    35 biostatistics
    36 bone sarcomas
    37 clinical sarcoma research
    38 collaborative strengths
    39 commitment
    40 complex STS
    41 conduct
    42 core
    43 description
    44 development
    45 developmental pilot projects
    46 developmental research programs
    47 diagnostics
    48 evaluation
    49 excellence
    50 excellent institution
    51 identification
    52 improvement
    53 institutions
    54 investigation
    55 key individual researchers
    56 main goal
    57 major projects
    58 major sarcoma
    59 malignant peripheral nerve sheath tumor
    60 maximum advantage
    61 mechanism
    62 multi-institution
    63 multiple researchers
    64 new projects
    65 non-profit organizations
    66 novel
    67 outcome
    68 pathology
    69 pediatric oncology
    70 plan
    71 planning
    72 predictors
    73 prevention
    74 profit consortium
    75 program
    76 project
    77 protein
    78 quantitative imaging biomarkers
    79 receptors
    80 research
    81 researchers
    82 sarcoma
    83 sarcoma therapy
    84 selection
    85 soft tissue
    86 spore application
    87 spores
    88 state
    89 support
    90 talented young investigators
    91 technological advances
    92 therapeutic response
    93 therapeutic strategies
    94 therapeutic target
    95 therapeutic window
    96 tissue
    97 translation
    98 translational advances
    99 translational goals
    100 treatment
    101 unprecedented cooperation
    102 schema:name SARC Sarcoma SPORE
    103 schema:recipient N5c24ce8776cb472ea8b319a9391b12a0
    104 sg:person.057030230.15
    105 schema:sameAs https://app.dimensions.ai/details/grant/grant.2699159
    106 schema:sdDatePublished 2021-01-20T02:59
    107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    108 schema:sdPublisher N4d012beb6cb34b3f9a906afbfeb05123
    109 schema:startDate 2012-09-26T00:00:00Z
    110 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9132690
    111 sgo:license sg:explorer/license/
    112 sgo:sdDataset grants
    113 rdf:type schema:MonetaryGrant
    114 N29edb7c50c5c497fb942f8fb0effe64b schema:name dimensions_id
    115 schema:value 2699159
    116 rdf:type schema:PropertyValue
    117 N41e04eba63aa49f0a50c3fa03e8830d5 schema:currency USD
    118 schema:value 11007192
    119 rdf:type schema:MonetaryAmount
    120 N4d012beb6cb34b3f9a906afbfeb05123 schema:name Springer Nature - SN SciGraph project
    121 rdf:type schema:Organization
    122 N5c24ce8776cb472ea8b319a9391b12a0 schema:member sg:person.057030230.15
    123 schema:roleName PI
    124 rdf:type schema:Role
    125 Nbd41c90c083b440ea49f67b2baaf9b78 schema:name nih_id
    126 schema:value U54CA168512
    127 rdf:type schema:PropertyValue
    128 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    129 rdf:type schema:DefinedTerm
    130 sg:person.057030230.15 schema:affiliation https://www.grid.ac/institutes/None
    131 schema:familyName BAKER
    132 schema:givenName LAURENCE HOWARD
    133 rdf:type schema:Person
    134 https://www.grid.ac/institutes/None schema:name SARC
    135 rdf:type schema:Organization
    136 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...